CytoDyn Inc.: Form 10-Q for the period ended Aug 31, 2024
Filed with the SEC on Oct 15, 2024 and accepted by EDGAR at Oct 15, 2024, 21:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2024-06-01 to 2024-08-31 | $22.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-06-01 to 2024-08-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-06-01 to 2024-08-31 | $19.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-06-01 to 2024-08-31 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-01 to 2024-08-31 | $0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-01 to 2024-08-31 | 1,198,287,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-06-01 to 2024-08-31 | $5.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-08-31 | $24.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-08-31 | $27.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-08-31 | $28.0m | us-gaap:Assets |
| Current liabilities | At period end2024-08-31 | $69.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-08-31 | $113.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-08-31 | $45.3m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-08-31 | −$85.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-013320. Last ingested by Listed: Oct 24, 2026, 14:53 ET. Listed shows no prices and gives no investment advice.